NRG-GU008: what clinicians are saying
apalutamide in node-positive prostate cancer after radical prostatectomy · NCT04134260 ↗ · Phase 3 · NRG Oncology
Radiation oncologists see NRG-GU008 as a way to close an evidence gap, not a basis for routine ARPI use; one highlights Formula 509’s inconclusive findings. Duration draws differing interpretations: one radiation oncologist tentatively favors shorter ADT because of possible other-cause mortality, whereas another draws on RADICALS-HD to explain the rationale for longer ADT. The mortality concern is not a trial finding; the sources reviewed for this edition describe no benefit or comparative-safety results from the trial.
Created with AI · how we check it
- edition 1
- commentary checked Nov 15, 2026
- 304 verified statements
This edition $1,950, with MCP access for your AI agent. Get this report
12 findings, and what sits behind each
01. Speakers look to INNOVATE to answer whether node-positive salvage treatment benefits from ARPI intensification
4 of the report's 42 cited clinicians · 19 statements from 4 speakers in 5 sources, 2 of them podcasts or videos · 9 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Metastasis-free survival (MFS), The comparison, Secondary endpoints, Population and setting, Safety and tolerability, Design and conduct.
02. One speaker questions whether INNOVATE's two-year hormonal course is too long
3 of the report's 42 cited clinicians · 11 statements from 3 speakers in 3 sources, all podcasts or videos · 9 passages
Limitations recorded: 2.
Draws on: The comparison, Population and setting, Primary endpoint: Metastasis-free survival (MFS), Safety and tolerability.
03. X accounts distinguish detectable-PSA salvage eligibility from the adjuvant-treatment debate
6 of the report's 42 cited clinicians · 9 statements from 6 speakers in 5 sources, 2 of them podcasts or videos · 9 passages
Limitations recorded: 3.
Draws on: Population and setting, The comparison, Design and conduct.
04. X accounts challenge the original dual-agent rationale; one trial-linked account explains reconsideration
4 of the report's 42 cited clinicians · 10 statements from 6 speakers in 5 sources · 10 passages
Limitations recorded: 3.
Draws on: The comparison, Design and conduct, Population and setting.
05. X accounts weigh radiotherapy flexibility against postoperative tolerability uncertainty
3 of the report's 42 cited clinicians · 11 statements from 3 speakers in 2 sources · 12 passages
Limitations recorded: 3.
Draws on: Safety and tolerability.
06. Speakers see participation as dependent on practical access and referral support
5 of the report's 42 cited clinicians · 22 statements from 5 speakers in 14 sources, 5 of them podcasts or videos · 20 passages
Limitations recorded: 3.
Draws on: Design and conduct, Population and setting, The comparison.
07. X accounts differ on adding an ARSI for PET-detected pelvic nodal persistence or relapse
5 of the report's 42 cited clinicians · 14 statements from 8 speakers in 1 source · 13 passages
Limitations recorded: 3.
Beyond the trial population
08. Speakers disagree on adjuvant treatment versus selective early salvage for postoperative pN1 disease
14 of the report's 42 cited clinicians · 40 statements from 20 speakers in 4 sources, 1 of them a podcast or video · 35 passages
Limitations recorded: 3.
09. X accounts dispute whether systemic benefit makes pelvic radiation unnecessary
2 of the report's 42 cited clinicians · 13 statements from 3 speakers in 1 source · 14 passages
Limitations recorded: 3.
10. X accounts question whether PSMA-directed focal treatment can substitute for early salvage fields
12 of the report's 42 cited clinicians · 25 statements from 15 speakers in 7 sources, 3 of them podcasts or videos · 26 passages
Limitations recorded: 3.
11. Speakers argue for risk-guided hormone use rather than uniform postoperative intensification
5 of the report's 42 cited clinicians · 48 statements from 5 speakers in 5 sources, 4 of them podcasts or videos · 34 passages
Limitations recorded: 3.
12. One X account proposes ctDNA-adapted escalation and de-escalation, while another questions the comparison with PSA
1 of the report's 42 cited clinicians · 4 statements from 1 speaker in 1 source · 4 passages
Limitations recorded: 3.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 12
4 of the report's 42 cited clinicians
Speakers look to INNOVATE to answer whether node-positive salvage treatment benefits from ARPI intensification
19 statements from 4 speakers in 5 sources, 2 of them podcasts or videos
- 19
- statements
- 9
- passages
- 5
- sources
- 4
- speakers
What the statements areViews 8Questions and uncertainty 3Clinical experience 1Comparisons 0Restated results and context 7Statement-to-passage links (a passage can back several statements)Supporting a statement 21Giving context 9Recorded with the findingLimitations: 3
2 posts and articles · 2 podcasts and video · 1 registry
Draws on: Primary endpoint: Metastasis-free survival (MFS), The comparison, Secondary endpoints, Population and setting, Safety and tolerability, Design and conduct.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
5 of the 12 findings and 124 of the 304 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Radiation oncologist · US
Video · Feb 2024
NPI checked · finding 1
A radiation oncologist encourages enrollment in NRG GU 008 INNOVATE wherever the study is open and awaits its results.
Radiation oncologist · US
Video · May 2024
NPI checked · finding 3
A radiation oncologist asks whether standard hormone therapy should be intensified with an ARPI in the adjuvant setting, identifies INNOVATE as investigating apalutamide added to radiation and hormone therapy, and believes this needs more trial work.
Statements as the report records them, by the speaker's role only. Full statements, speaker names and links to each source are in the report.
Abbreviations (8)
ADT, androgen deprivation therapy; ARPI, androgen receptor pathway inhibitor; HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; PET, positron emission tomography; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen.
The full NRG-GU008 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What do clinicians say they need to see from INNOVATE on metastasis-free survival, quality of life and short- and long-term toxicity before routinely adding apalutamide to salvage radiation and hormone therapy for pathologically node-positive prostate cancer with detectable PSA after prostatectomy?
From finding F1 (19 statements from 4 speakers in 5 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 61commentary sources screened
- 30sources cited by verified statements
- 59named in screened sources
- 58speakers cited in the report
- 54cited speakers with a verified identity
42 cited clinicians, speakers with a confirmed clinical role, of them 42 physicians. By role and specialty:
- 20 physician, Radiation oncology
- 9 physician, specialty not confirmed
- 6 physician, Surgical oncology
- 4 physician, Medical oncology
- 3 physician, Urology
Also in the sources: 3 organizational or shared accounts, not counted as people.
- 304verified statements, each linked to its source
- 236of them from speakers with a confirmed clinical role
- 12findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 12 | Titles free |
| Detailed analysis | 14 sections | Paid |
| Verified statements with short source quotes and links | 304 | Paid |
| Who said each statement: the cited speakers | 58 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 42 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 54 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 15 | Free |
| Sources with links | 30 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
15 discussed · 0 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Metastasis-free survival (MFS) | 6 | 2 |
| Secondary endpoints | 8 | 5 |
| Population and setting | 14 | 9 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 17 | 9 |
| Safety and tolerability | 14 | 6 |
| Design and conduct | 16 | 10 |
| Adjuvant versus early-salvage timing and control-arm interpretation | 42 | 4 |
| Systemic addition versus replacement of local treatment | 18 | 2 |
| Advanced imaging, stage migration and limits of negative scans | 21 | 8 |
| Radiation fields, fractionation, focal substitution and boosts | 34 | 5 |
| Patient selection, genomic risk and postoperative work-up | 38 | 7 |
| Alternative regimens for PET-detected pelvic nodal persistence or relapse | 14 | 1 |
| Enrollment access, imaging costs, referrals and patient information | 26 | 17 |
| Duration, evidence transfer and clinically meaningful benefit | 41 | 6 |
| Proposed ctDNA-adapted escalation and de-escalation research | 4 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
304 verified statements from 30 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 128 statements · 42% | ||||
| YouTube | 128 | 9 | 11 | |
| Podcasts | 0 | 0 | 2 | |
| Posts · 175 statements · 58% | ||||
| X threads | 175 | 20 | 47 | |
| Bluesky threads | 0 | 0 | 1 | |
| Primary sources · 1 statement · 0%cited for context, not screened | ||||
| Registry | 1 | 1 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 11 / quarter
- Screened window
- Nov 9, 2019 → Oct 21, 2026
- Cited window
- Oct 16, 2020 → Oct 21, 2026
- Retrieved
- Nov 15, 2026
The trial
from ClinicalTrials.gov- Title
- Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
- Registry
- NCT04134260
- Study IDs
- NRG-GU008 · NCI-2019-06838 (CTRP (Clinical Trial Reporting Program)) · U10CA180868
- Sponsor
- NRG Oncology
- Collaborators
- National Cancer Institute (NCI)
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Active, not recruiting
- Enrollment
- 586 estimated
- Registered
- 2019-10-22
- Start
- 2020-04-16 actual
- Primary completion
- 2026-11-01 estimated
- Primary endpoint
- Metastasis-free survival (MFS)
- Interventions
- 10 registered
More on: Prostate cancer
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- For 2 recordings, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
- Not yet captured in this edition: a view on tailoring salvage treatment because not every patient needs intensification; a view on clinically actionable recurrence and the factors guiding salvage-treatment decisions; a view on variation in imaging work-up and treatment initiation for recurrence after prostatectomy and radiotherapy; a question about avoiding unnecessary therapy and selecting treatment intensity as advanced imaging changes staging; a view on distinguishing recurrence from actionable progression when assessing clinically meaningful salvage-treatment outcomes; a question about imaging-positive disease prevalence among patients considered for salvage radiotherapy.
- 1 more clinician view in the sources used in this report is not yet captured as evidence in this edition.
- 135 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
Show all 16 known gaps +Fewer −
- Further source limits: 38 sources about other trials or topics are not included; discussion that uses a name the trial shares with other things, without the trial's condition or setting, may be missing.
- The sources reviewed for this edition are not a representative sample of HCP opinion; no prevalence, consensus proportion or independent-clinician count can be inferred.
- Discussion that did not use the searched trial names or identifiers may be missing. Coverage of unnamed references and transcription variants is therefore incomplete.
- Some media passages cannot be confidently assigned to a named speaker. Their views remain attributed to the discussion or presentation rather than to a roster participant.
- Some comments qualifying salvage-radiotherapy toxicity and the distinction between biochemical recurrence and acting on recurrence are not fully represented, limiting completeness on those issues.
- No INNOVATE efficacy or comparative-safety readout is described. Other-study findings, personal experience, hypotheses and cure-rate aspirations are not results of INNOVATE.
- Full protocol and detailed amendment documentation were unavailable. Historical statements about drugs, radiation modalities, imaging and geographic participation should not be treated as current requirements.
- Recruitment messages span several years and include both a completion announcement and a later description of an ongoing study. They do not establish live enrollment status.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Several important arguments extrapolate from broader salvage, adjuvant, clinically node-positive or intact-prostate populations. Those boundaries limit application to INNOVATE's detectable-PSA postoperative pN-positive population.
- Reposts, repeated statements and excerpts from the same presentation do not provide additional independent support.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 15, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. NRG-GU008 (NCT04134260): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 15, 2026. https://www.erudio.com/reports/nrg-gu008-nct04134260
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "NRG-GU008" (NCT04134260), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "nrg-gu008-nct04134260". If you cannot make requests, read https://www.erudio.com/reports/nrg-gu008-nct04134260.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT04134260", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT04134260 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/nrg-gu008-nct04134260.json
curl https://www.erudio.com/reports/nrg-gu008-nct04134260.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "nrg-gu008-nct04134260" })release df47c56de794af406b0f820858d846acf1688a069b15348a311111a9339888f8
Questions
How much does the NRG-GU008 report cost?
One edition costs $1,950 (Deep · 304 verified statements · 236 from 42 confirmed clinicians). With updates: 3 months $3,400, 6 months $4,900, 12 months $6,800. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the NRG-GU008 report cover?
304 statements from 30 sources (9 videos, 20 posts, 1 registry record), 236 of them from 42 confirmed clinicians, each linked to its source. Commentary checked Nov 15, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the NRG-GU008 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "nrg-gu008-nct04134260" }) previews it and create_order({ "report": "nrg-gu008-nct04134260", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the NRG-GU008 report?
Edition 1 (version 1.0.0), accepted Nov 15, 2026 UTC; last checked for new commentary Nov 15, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.